Yifeng Pharmary(SH:603939) Bank of China Securities·2025-09-12 03:51Investment Rating - The report maintains a "Buy" rating for the company, with a market price of RMB 26.18 and a sector rating of "Outperform" [1][4]. Core Views - The company reported stable performance in the first half of 2025, with a slight decrease in revenue but an increase in net profit, indicating effective cost reduction and efficiency strategies [4][6]. - The company is expected to benefit from ongoing online business growth and diversified innovations, which are anticipated to drive long-term development [4][9]. Financial Summary - For the first half of 2025, the company achieved revenue of RMB 11.72 billion, a year-on-year decrease of 0.35%, while net profit attributable to shareholders was RMB 880 million, a year-on-year increase of 10.32% [4][9]. - The company adjusted its profit forecast for 2025-2026, estimating net profits of RMB 1.75 billion and RMB 2.07 billion respectively, reflecting a downward revision from previous estimates [6][8]. - The projected earnings per share (EPS) for 2025-2027 are RMB 1.44, RMB 1.70, and RMB 1.87, with corresponding price-to-earnings (PE) ratios of 18.1, 15.4, and 14.0 [6][8]. Business Performance - The retail segment generated revenue of RMB 10.20 billion in the first half of 2025, a decrease of 1.91%, while the franchise and distribution business saw revenue growth of 17.20% to RMB 1.17 billion [9]. - The company closed 272 stores and opened 81 new ones, indicating a strategic adjustment in response to market conditions [9]. - Membership numbers increased to 110 million, with member sales accounting for 84.93% of total sales, showcasing strong customer loyalty [9]. Market Position and Strategy - The company continues to implement a "regional focus" strategy, enhancing its market presence across multiple provinces and cities [9]. - The O2O (Online to Offline) business model is being expanded, with over 10,000 O2O stores established, contributing to significant online sales growth [9].